CPA4 overexpression correlates with poor prognosis and tumor progression in endometrial cancer
CPA4 emerges as a vital biomarker for diagnosing and prognosing endometrial cancer, presenting a novel pathway for research and clinical application. The study highlights its potential as a clinical tool, paving the way for improved patient management and treatment strategies in endometrial cancer.
Authors
- Jingying Zheng (ORCID: https://orcid.org/0000-0002-7790-4775)
- Longyun Wang
- Lijing Zhao (ORCID: https://orcid.org/0000-0002-3190-7399)
- Zeyu Wang (ORCID: https://orcid.org/0000-0002-1223-1661)
- Kai You Wang (ORCID: https://orcid.org/0000-0002-6170-4744)
- Hao Lv
- Kang He (ORCID: https://orcid.org/0000-0001-9621-9258)
- Shan Wu (ORCID: https://orcid.org/0009-0002-6683-7359)
- Tingyu Zhang (ORCID: https://orcid.org/0000-0002-2277-8871)
Institutions
- Jilin University (CN)
- Second Affiliated Hospital of Jilin University (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
Publication Details
- Journal
- European journal of medical research
- Published
- 2025-03-15
- DOI
- https://doi.org/10.1186/s40001-025-02293-0
- Citations
- 4
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 6.07